VENCLEXTA (venetoclax tablets) is a first-in-class treatment that targets BCL-2 to help restore the process of apoptosis 1

  • The ability to evade apoptosis is an important hallmark of cancer. Overexpression of BCL-2 has been demonstrated in CLL cells and has been associated with resistance to chemotherapy 1,22
  • Overexpressed BCL-2 allows hematologic cancer cells to evade apoptosis by sequestering pro-apoptotic proteins
  • VENCLEXTA selectively binds to BCL-2, displacing pro-apoptotic proteins and triggering events that lead to apoptosis

GAZYVA® (obinutuzumab) and rituximab are monoclonal antibodies that target the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes 20,21

  • Upon binding to CD20, the antibodies mediate B-cell lysis
  • Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)